“We are delighted and grateful to have the continuing support of GCIC,” said Jake Orville, president and chief executive of Prognostix. “GCIC’s first grant enabled Prognostix to make significant progress with both our CardioMPO™ and dysfunctional HDL products. We were pleased to have completed each of the milestones laid out for us by GCIC for the first grant and look forward to a strong, ongoing relationship with the center.”
With the assistance of GCIC’s second grant, Prognostix will complete its FDA 510(k) submission to expand the use of its CardioMPO(TM) product outside of acute-care settings and advance the development of its valuable dysfunctional HDL biomarker, which it expects to launch in 2009.
